PTCT News and Press, PTC Therapeutics Inc. From 08/04/23

2023-08-04 00:05:23 ET PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Conference Call August 03, 2023 04:30 PM ET Company Participants Ron Aldridge - Senior Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer...

2023-08-03 16:16:14 ET PTC Therapeutics press release ( NASDAQ: PTCT ): Q2 GAAP EPS of -$2.66 misses by $1.04 . Revenue of $213.8M (+28.8% Y/Y) beats by $7.86M . Cash, cash equivalents, and marketable securities was $337.9 million on June 30, 2023, compared to ...

PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results PR Newswire – Second-quarter 2023 total revenue of $214 million , representing 29% year-over-year growth – – Positive APHENITY and PIVOT-HD data readouts in...

2023-07-28 13:22:08 ET Larimar Therapeutics ( NASDAQ: LRMR ), which has a candidate in phase 2 for Friedreich's Ataxia ("FA"), is up 22% in Friday afternoon trading, a beneficiary of Biogen's ( BIIB ) announcement to acquire Reata Pharmaceuticals ( RETA ) for more th...

2023-07-21 14:53:45 ET PTC Therapeutics ( NASDAQ: PTCT ) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency, recommended extending the marketing authorization for its Roche ( OTCQX:RHHBY )-partnered treatment Evrysdi to include infants ...

CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy PR Newswire - Following ratification by the European Commission, Evrysdi will be available to treat all spinal muscular atrophy patients, including babies from birth - SOUTH PL...

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , July 20, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call...

PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize PR Newswire -- Dr. Jacobson recognized for his pioneering work in nonsense-mediated mRNA decay -- SOUTH PLAINFIELD, N.J. , July 19, 2023 /PRNewswire/ -- PTC Therape...

2023-07-17 17:09:58 ET PTC Therapeutics ( NASDAQ: PTCT ) said on Monday that it had appointed Pierre Gravier as chief financial officer. Gravier previously served as a managing director in the healthcare group of Perella Weinberg Partner. Press Release For f...

PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer PR Newswire SOUTH PLAINFIELD, N.J. , July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Grav...